1. JAK/STAT Signaling
    Protein Tyrosine Kinase/RTK
  2. EGFR

EGFR

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). All EGFR family members are characterized by a modular structure consisting of an extracellular ligand-binding domain, a single hydrophobic transmembrane region, and the intracellular part harbouring the highly conserved tyrosine kinase domain. The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation, differentiation, cell motility, and survival. Ten growth factors and their ErbB specificities are: EGF, amphiregulin (AR), and TGF bind ErbB-1; betacellulin, heparin binding EGF-like growth factor, and epiregulin bind both ErbB-1 and ErbB-4; the neuregulins (also called heregulins and Neu differentiation factors) NRG-1 and NRG-2 bind ErbB-3 and ErbB-4; and NRG-3 and NRG-4 bind ErbB-4. No known ligand binds ErbB-2. The three best characterized signaling pathways induced through ErbBs are Ras–mitogen-activated protein kinase (Ras-MAPK), phosphatidylinositol 3_ kinase-protein kinase B (PI3K-PKB/Akt), and phospholipase C–protein kinase C (PLC-PKC) pathways.

EGFR Isoform Specific Products:

  • EGFR/ErbB1/HER1

  • ErbB2/HER2

  • ErbB3/HER3

  • ErbB4/HER4

EGFR 相关产品 (98):

Cat. No. Product Name Effect Purity
  • HY-15772
    AZD-9291 Inhibitor 99.95%
    AZD-9291是一种不可逆和突变的选择性的 EGFR 抑制剂,抑制EGFRL858R 和EGFRL858R/T790MIC50 分别为12 和 1 nM。
  • HY-50895
    Gefitinib Inhibitor 99.89%
    Gefitinib 是一种有效的表皮生长因子受体 (EGFR) 抑制剂,在 NR6wtEGFR 细胞中 IC50 值为 2-37 nM。
  • HY-10261
    Afatinib Inhibitor 99.99%
    Afatinib (BIBW 2992) 是不可逆的 EGFR 家族抑制剂,抑制EGFRwt,EGFRL858R,EGFRL858R/T790M 和 HER2的 IC50 分别为0.5 nM,0.4 nM,10 nM 和 14 nM。
  • HY-50896
    Erlotinib Inhibitor >98.0%
    Erlotinib是一种治疗非小细胞肺癌的药物。抑制纯化 EGFR 激酶的 IC50 为2 nM。
  • HY-12000
    AG-490 Inhibitor 99.84%
    AG-490是酪氨酸激酶抑制剂,其抑制EGFRStat-3JAK2/3
  • HY-109061
    Lazertinib Inhibitor 98.00%
    Lazertinib 是一种有效,可逆,可口服,可透过血脑屏障的,突变体选择性的第三代 EGFR 酪氨酸激酶抑制剂,可用于非小细胞肺癌的研究。
  • HY-19985
    PF-06459988 Inhibitor 98.72%
    PF-06459988 是 T790M-Containing EGFR Mutants 不可逆性抑制剂 。
  • HY-112299
    TAS6417 Inhibitor 98.02%
    TAS6417 是表皮生长因子受体 (EGFR) 的抑制剂,也是治疗非小细胞肺癌的有效候选药物,其 IC50 值为 1.1-8.0 nM。
  • HY-50898
    Lapatinib Inhibitor 99.83%
    Lapatinib (GW572016)是有效的 EGFRErbB2 抑制剂,IC50 分别为10.2 和 9.8 nM。
  • HY-32721
    Neratinib Inhibitor 98.84%
    Neratinib 是一种可口服的,不可逆的 tyrosine kinase 抑制剂,能够抑制 HER2 和 EGFR 的活性,IC50 值分别为 59 nM 和 92 nM。
  • HY-14596
    Genistein Inhibitor 99.64%
    Genistein是一种大豆异黄酮,是一种多重的酪氨酸激酶 (tyrosine kinases) 抑制剂,是对多种癌症的化疗剂,主要通过改变细胞凋亡,细胞周期和血管生成以及抑制转移。
  • HY-12008
    Erlotinib Hydrochloride Inhibitor 99.93%
    Erlotinib 抑制 EGFR 激酶的 IC50 为 2 nM。
  • HY-P9907
    Trastuzumab Inhibitor 99.30%
    Trastuzumab 是一种人源化单克隆抗体,其以高亲和力与 HER2 选择性结合。Trastuzumab 已被批准用于治疗 HER2 阳性转移性乳腺癌和 HER2 阳性胃癌。
  • HY-13653
    (-)-Epigallocatechin Gallate Inhibitor 99.60%
    (-)-Epigallocatechin Gallate 是一种天然的多酚黄酮类化合物,能够抑制 EGFRHER2HER3 的活化,具有抗肿瘤活性。
  • HY-13272
    Dacomitinib Inhibitor 99.83%
    Dacomitinib 是一种特异,不可逆的 ERBB 家族抑制剂,作用于 EGFRERBB2ERBB4IC50 分别为 6 nM,45.7 nM 和 73.7 nM。
  • HY-13524
    AG-1478 Inhibitor 99.74%
    AG-1478 是一种选择性的 EGFR 酪氨酸激酶抑制剂,IC50 为 3 nM。
  • HY-15772A
    AZD-9291 mesylate Inhibitor 99.94%
    AZD-9291 mesylate是不可逆的突变体选择性 EGFR 抑制剂;对EGFRL858R 和EGFRL858R/T790MIC50 值分别为12 和 1 nM。
  • HY-P9905
    Cetuximab Inhibitor 99.70%
    Cetuximab 是一种单克隆抗体,能够抑制 EGFR,具有抗肿瘤作用。
  • HY-16069
    Irbinitinib Inhibitor 98.53%
    Irbinitinib (ARRY-380; ONT-380)是高效的选择性的HER2抑制剂,IC50值为8 nM。
  • HY-10261A
    Afatinib dimaleate Inhibitor 99.31%
    Afatinib dimaleate是不可逆的 EGFR 家族抑制剂,抑制EGFRwt,EGFRL858R,EGFRL858R/T790M 和 HER2的 IC50 分别为0.5 nM,0.4 nM,10 nM 和 14 nM。
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.